M

ME Therapeutics Holdings
METX

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
CA$120.20M
EV
CA$118.87M
Shares Outstanding
36.56M
Beta
-0.61
Industry
-

Wall Street View

Analyst Rating
-
Analyst Target Price
-
Number of Analysts
0
P/E E
-
P/Revenue E
-

Historical 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Forecasted 3Y Growth Rate

Revenue
-
EPS
-
Operating Cash Flow
-
Free Cash Flow
-

Margins & Returns

Gross Margin E
-
Net Profit Margin E
-
ROE E
-
ROCE
-

Dividends

DPS E
-
Payout Ratio E
-
Div. Yield E
-
DPS Last 3Y CAGR
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About ME Therapeutics Holdings Inc.

gainify

M

ME Therapeutics Holdings Inc.

METX

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein i...

Sector

Industry

CEO

Dhanji, Salim

Employees

IPO Date

Headquarters

177 Robson Street, Vancouver, British Columbia, V6B 0N3, Canada

📊 Stock Price & Performance

Review the recent METX stock performance trends:Past 3 Months: The stock has +11.71%. Last updated: December 31, 2025 at 11:42 PM Eastern Time

ME Therapeutics Holdings (METX) is considered a low volatility stock. It has a beta of -0.61, which means it typically moves in the opposite direction of the broader market, with a magnitude of approximately 0.61 times the market's movement. Last updated: December 31, 2025 at 11:42 PM Eastern Time

💰 Financial Metrics & Reports

The current ME Therapeutics Holdings (METX) market capitalization is approximately CA$120.20M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, ME Therapeutics Holdings's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:42 PM Eastern Time

📅 Earnings & Dividends

ME Therapeutics Holdings (METX) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CA$0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

📈 Analyst Information

Based on the latest available analyst coverage, ME Therapeutics Holdings (METX) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice.

Like other publicly traded stocks, ME Therapeutics Holdings (METX) shares are bought and sold on stock exchanges such as CNSX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for ME Therapeutics Holdings (METX) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

ℹ️ Company Information

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add METX to your watchlist.

ME Therapeutics Holdings trades under the ticker symbol METX on the CNSX stock exchange. The ticker METX is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

ME Therapeutics Holdings (METX) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest ME Therapeutics Holdings (METX) stock peers based on overlapping products, services, and competitive dynamics:Helix BioPharma (HBP)Medicenna Therapeutics (MDNA)BriaCell Therapeutics (BCT)Biomark Diagnostics (20B)enGene Holdings (ENGN)Repare Therapeutics (RPTX)Waverley Pharma (WAVE) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to ME Therapeutics Holdings.

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2026 Gainify. All rights reserved.